🎉📣FSD Pharma's Research and Clinical Advisory Board📢Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical Advisory Board. FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board.
Dr. Fish, an accomplished immunologist and member of the Government of Canada's Expert Scientific Panel to the Chief Scientific Advisor, brings to FSD Pharma valuable experience that will help the company continue to develop FSD-PEA, its proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis.
Dr. Lakshmi P. Kotra, B.Pharm. (Hons), Ph.D., Chief Executive Officer of Lucid Psycheceuticals Inc., FSD Pharma's wholly-owned subsidiary, remarked, "I am thrilled to welcome Dr. Eleanor Fish to our team." "One of Eleanor's main goals is to learn more about the onset and treatment of autoimmune disorders like multiple sclerosis and rheumatoid arthritis. Her decades of experience in translational research will tremendously benefit FSD's existing and future pipelines, and her skills and insights will be highly important as we continue to progress our FSD-PEA and Lucid-MS programmes."
Dr. Fish is a professor in the Department of Immunology at the University of Toronto, as well as the Associate Chair of International Initiatives and Collaborations and an Emerita Scientist at the University Health Network's Toronto General Hospital Research Institute. She earned a B.Sc. from the University of Manchester in the United Kingdom, an M.Phil. from King's College at the University of London, and a Ph.D. from the University of Toronto's Institute of Medical Sciences. Dr. Fish has received multiple international accolades for her scientific contributions and has authored over 170 peer-reviewed scientific publications that have been published in peer-reviewed journals around the world.
“I am energized by this opportunity to assist FSD Pharma in advancing the development of its next- generation therapeutics in pursuit of a healthier world,” said Dr. Fish.